GRANULES INDIA —pharmaceutical company Finished Dosages (FD)

Strengths Strong FY26 growth: Consolidated revenue from operations increased 20% YoY to ₹5,365.6 Cr. Profitability improved: FY26 EBITDA rose 25% to ₹1,185.1 Cr, while PAT increased 19% to ₹595.0 Cr. Vertically integrated model across API → PFI → Finished Dosage provides greater control over manufacturing and supply chain. Diversified product portfolio: Core molecules include Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol, alongside newer API and CDMO businesses. Weaknesses North America remains the largest market, creating geographical concentration risk despite improving diversification. The business has meaningful exposure to generic-drug pricing pressure. Pharmaceutical manufacturing requires continuous investment in regulatory compliance, quality systems and capacity. Opportunities CDMO/CRAMS expansion can create a higher-value growth engine beyond the traditional generic business. Increasing demand for complex generics and specialty pharmaceuticals can support margin expansion. The company's peptide platform provides an opportunity to participate in a rapidly growing pharmaceutical segment. Europe is showing strong momentum, offering potential for further geographical diversification. Threats U.S. FDA/regulatory risk remains important because of the company's significant exposure to regulated markets. Generic-drug price erosion and intense competition can pressure margins. Dependence on North America makes the company sensitive to U.S. healthcare-policy and pricing changes. Raw-material costs, currency movements and supply-chain disruptions can affect profitability. Competition in CDMO, peptides and complex generics could require substantial continuing R&D expenditure. Delays in regulatory approvals or commercialization of new products could affect expected growth.